New breath test shows possible biomarker for early-stage liver disease diagnosis
A natural compound called limonene, which is found in oranges and lemons, could be indicative in early-stage diagnosis of liver disease, according to new research. Patients with this illness do not often present with symptoms until the disease is advanced. Even then diagnosis is difficult and the symptoms and signs are often general and can be mistaken for other pathologies. For advanced cirrhosis liver, transplant is the only treatment. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 11, 2015 Category: Science Source Type: news

Genus : the Pink Bacterium—a Case Report
We describe a 58-year-old male with a history of cirrhosis secondary to alcoholic hepatitis who had blood cultures positive for Roseomonas gilardii and responded favorably to therapy with a fluoroquinolone antibiotic. (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - August 4, 2015 Category: Microbiology Authors: Roger Nehaul, Ashley H. Davis-Yadley, Shreya Narayanan, John T. Sinnot Tags: Case Report Source Type: news

7 Numbers That Show The Fight Against Hepatitis Is Far From Over
July 28 is World Hepatitis Day, a sorely-needed awareness campaign for diseases that affect more than 400 million people alive today. In the U.S., more people die from hepatitis C than they do from HIV/AIDS. And despite being preventable with vaccine, hepatitis B causes an estimated 1 million deaths every year and is the leading cause of liver cancer worldwide. Despite these shocking numbers, the virus is little understood and discussed, and that’s got to change, according to Dr. H. Nina Kim, director of the Madison HIV/Hepatitis Coinfection Clinic in Washington. “In some ways, the HIV epidemic is tie...
Source: Science - The Huffington Post - July 28, 2015 Category: Science Source Type: news

Good news for people suffering from fatty liver disease: Resistance training can help
Approximately 30% of the population suffer from fatty liver disease, the most common liver disease in the Western world. The disease can lead to inflammation and cirrhosis of the liver. A new study has found that gym training, and not only aerobic exercises, can help reduce liver fat (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 27, 2015 Category: Science Source Type: news

Interferon-Free Treatment for HCV Genotype 4 Approved (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD The FDA has approved a ombitasvir/paritaprevir/ritonavir tablet (marketed as Technivie) for treating hepatitis C virus genotype 4 in patients without cirrhosis or scarring. The … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 27, 2015 Category: Primary Care Source Type: news

FDA approves Technivie for treatment of chronic hepatitis C genotype 4
The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis). (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 24, 2015 Category: American Health Source Type: news

Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - June 29, 2015 Category: Pharmaceuticals Source Type: news

Primary Biliary Cirrhosis
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 25, 2015 Category: Journals (General) Source Type: news

New book on The Hepatitis B and Delta Viruses from CSHLPress
(Cold Spring Harbor Laboratory) The Hepatitis B and Delta Viruses, from CSHLPress, examines all aspects of HBV and HDV infections and their management. Contributors discuss the HBV and HDV life cycles, their unique characteristics (e.g., the formation of HBV cccDNA), the immune responses they elicit, and the challenges they present to the development of antiviral treatments. The molecular mechanisms that lead to liver cirrhosis and hepatocellular carcinoma are reviewed, as are factors that influence the severity of the disease. Conventional treatments are also described. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 18, 2015 Category: Global & Universal Source Type: news

Call to extend hepatitis C drugs access after £190m funding boost
A charity has called for NHS England to allow all hepatitis C patients to access new treatments. It comes after the arm’s length body announced a much delayed commissioning policy for cirrhosis. (Source: HSJ)
Source: HSJ - June 17, 2015 Category: UK Health Source Type: news

XTuit Pharmaceuticals Closes $22 Million Series A Financing to Advance Novel Microenvironmental Modulators for Cancers and Fibrotic Disorders
Funding to Support Early Clinical Proof-of-Concept for Lead Products for Immuno-Oncology and Liver Cirrhosis/Nonalcoholic Steatohepatitis (NASH) Round led by New Enterprise Associates and joined by syndicate including founding investor Polaris Partners ... Biopharmaceuticals, Oncology, Venture CapitalXTuit Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 11, 2015 Category: Pharmaceuticals Source Type: news

Thousands more patients to be cured of hepatitis C
Thousands of patients in England with cirrhosis caused by the hepatitis C virus will now be able to access new treatment options which can cure the virus and therefore prevent further damage to the liver, including the potential of end stage liver disease or cancer. More .... (Source: NHS Networks)
Source: NHS Networks - June 11, 2015 Category: UK Health Authors: Maria Axford Source Type: news

Super Nutrient’s Liver Surprise
I was one of the first doctors to talk about the incredible benefits of the super-nutrient pyrroloquinoline quinone, or PQQ for short. I was also one of the first doctors to recommend it to patients. Now I recommend this essential nutrient and powerful antioxidant to almost everyone who comes to see me at my wellness clinic. Researchers have only just recently begun to understand the many important roles of PQQ on the body’s cellular processes. Not only does it possess extraordinary energy-giving qualities and have the power to ease nerve pain and battle Alzheimer’s, it has the potential to become the world&rsq...
Source: Al Sears, MD Natural Remedies - June 10, 2015 Category: Complementary Medicine Authors: Dr. Al Sears Tags: Anti-Aging Cancer CoQ10 Source Type: news

NHS England extends early access scheme to include hep C
Thousands of people with hep C-related cirrhosis to benefit from £190m in new drugsRelated items from OnMedicaMelanoma drug is first to be fast tracked under NHS early access schemeHalf of people with hepatitis C don’t know they have itWidespread hepatitis C screening may do more harm than goodHepatitis C screeningAntivirals cut liver cancer risk after hepatitis C (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 10, 2015 Category: UK Health Source Type: news

Abbott launches Hepatitis C awareness, diagnosis programme
Hepatitis C virus causes chronic infection leading to cirrhosis and may cause liver cancer. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 9, 2015 Category: Pharmaceuticals Source Type: news

Mayo Clinic Q and A: Medication may help slow progression of PBC
DEAR MAYO CLINIC: I was diagnosed with primary biliary cirrhosis three months ago. I don’t have any symptoms yet but wonder what I should look for. Are there things I can do to slow its progression? ANSWER: Your situation is common. Most people diagnosed with primary biliary cirrhosis, or PBC, in its early stages do [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 6, 2015 Category: Databases & Libraries Source Type: news

4 Easy Ways To Beat Aging
I’ve been hearing it nearly all of my life: Save your money for your “old age.” I’m sure that well-meaning friends and relatives have been telling you the same thing for years, too. But more than 2,100 years ago, the Roman philosopher Virgil hit the nail on the head when he said: “The greatest wealth is health.” And these aren’t just fancy words of philosophical wisdom. They are very good practical advice. You should be saving something much more important than money – no matter what your age. I’m talking about saving your telomeres, those tiny “countdown clocks&r...
Source: Al Sears, MD Natural Remedies - June 3, 2015 Category: Complementary Medicine Authors: Dr. Al Sears Tags: Anti-Aging DNA telomerase telomeres Source Type: news

Ledipasvir plus sofosbuvir: Hint of added benefit in further patient group
Documents subsequently submitted by the manufacturer show an advantage in sustained virologic response also for hepatitis C infection of genotype 1 with HIV coinfection without cirrhosis of the liver, reviewers report. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 22, 2015 Category: Science Source Type: news

Ledipasvir plus sofosbuvir: Hint of added benefit in further patient group
(Institute for Quality and Efficiency in Health Care) The documents subsequently submitted by the manufacturer show an advantage in sustained virologic response also for hepatitis C infection of genotype 1 with HIV coinfection without cirrhosis of the liver. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 22, 2015 Category: Global & Universal Source Type: news

UT Health Science Center San Antonio doctor plays key role in FDA expediting hep C drugs
(University of Texas Health Science Center at San Antonio) The US Food and Drug Administration has granted amended Breakthrough Therapy Designation for a promising drug combination to treat the sickest hepatitis C patients -- those with advanced cirrhosis or who have had a liver transplant but the virus returned. The designation expedites drug development based on early results of the ALLY-1 clinical trial presented by Fred Poordad, M.D., from The University of Texas Health Science Center at San Antonio, at The International Liver CongressTM. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 20, 2015 Category: Cancer & Oncology Source Type: news

New Drug Boosts Response in Primary Biliary Cirrhosis (CME/CE)
(MedPage Today) -- Called obeticholic acid, the investigational agent is a farnesoid X receptor agonist. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - May 20, 2015 Category: Gastroenterology Source Type: news

PBC Patients Face High Wait-List Mortality (CME/CE)
(MedPage Today) -- Consider allocation of exception MELD points to primary biliary cirrhosis patients on transplant list. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - May 18, 2015 Category: Gastroenterology Source Type: news

NASH Cirrhosis May Underlie Liver Cancer (CME/CE)
(MedPage Today) -- Cryptogenic hepatocellular cancer could develop through non-alcoholic steatohepatitis pathway. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 18, 2015 Category: Cardiology Source Type: news

Georgia State research paves way for early detection of liver cancer
(Georgia State University) Led by Georgia State University, researchers have developed the first robust and noninvasive detection of early stage liver cancer and liver metastases, in addition to other liver diseases, such as cirrhosis and liver fibrosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 14, 2015 Category: Cancer & Oncology Source Type: news

New Regimen Appears Effective for HCV Plus CirrhosisNew Regimen Appears Effective for HCV Plus Cirrhosis
New interferon-free regimens showed a high rate of sustained virologic response among patients with chronic HCV, including those who had been treated previously or had compensated cirrhosis. Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 7, 2015 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Hispanics' health in the United States: Report
The first national study on Hispanic health risks and leading causes of death in the United States by the Centers for Disease Control and Prevention showed that similar to non-Hispanic whites (whites), the two leading causes of death in Hispanics are heart disease and cancer. Fewer Hispanics than whites die from the 10 leading causes of death, but Hispanics had higher death rates than whites from diabetes and chronic liver disease and cirrhosis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 6, 2015 Category: Science Source Type: news

Interferon-free therapy clears hepatitis C in 93 percent of patients in trial
A 12-week dose of an investigational three-drug hepatitis C combination cured the virus in 93 percent of patients with liver cirrhosis who hadn't previously been treated, according to a study. For most of the past 20 years, therapies for hepatitis C relied on interferon drugs, which require regular injections for as long as one year and trigger miserable, flu-like side effects that prompt many patients to quit the regimen. Some patients aren't eligible for this treatment if they have anemia, low platelets or other conditions (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 5, 2015 Category: Science Source Type: news

Studies show effectiveness of combo treatment for HCV patients with, without cirrhosis
Patients with chronic hepatitis C virus genotype 1 infection and with or without cirrhosis achieved high rates of sustained virologic response after 12 weeks of treatment with a combination of the direct-acting-antiviral drugs daclatasvir, asunaprevir, and beclabuvir, researchers report. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 5, 2015 Category: Science Source Type: news

Studies show effectiveness of combo treatment for HCV patients with, without cirrhosis
(The JAMA Network Journals) In two studies appearing in the May 5 issue of JAMA, patients with chronic hepatitis C virus genotype 1 infection and with or without cirrhosis achieved high rates of sustained virologic response after 12 weeks of treatment with a combination of the direct-acting-antiviral drugs daclatasvir, asunaprevir, and beclabuvir. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 5, 2015 Category: Infectious Diseases Source Type: news

Interferon-free therapy clears hepatitis C in 93 percent of patients in trial
(Duke University Medical Center) A 12-week dose of an investigational three-drug hepatitis C combination cured the virus in 93 percent of patients with liver cirrhosis who hadn't previously been treated, according to a study in the May 5, 2015, issue of The Journal of the American Medical Association. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 5, 2015 Category: Infectious Diseases Source Type: news

Cardiovascular Burden, Death Rises With Fatty Liver StageCardiovascular Burden, Death Rises With Fatty Liver Stage
As simple fatty liver disease progresses to steatohepatitis and then to fibrosis and cirrhosis, the risk for death and cardiovascular comorbidity increase, report researchers. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 1, 2015 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Software Helps Predict Decompensation Risk in CirrhosisSoftware Helps Predict Decompensation Risk in Cirrhosis
A CT-derived liver surface nodularity score can help predict the risk for decompensation and death in patients with cirrhosis, new research has shown. Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - April 30, 2015 Category: Gastroenterology Tags: Radiology News Source Type: news

HCV Drug Combo Succeeds in Advanced Disease (CME/CE)
(MedPage Today) -- Is treatment best option for all HCV patients with cirrhosis or post-transplant recurrence? (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - April 28, 2015 Category: Gastroenterology Source Type: news

Drinking just one or two alcoholic drinks a day linked to liver disease
According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. A new worldwide study has shown the significant influence of daily drinking on this disease burden. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 26, 2015 Category: Science Source Type: news

Sofosbuvir and peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients
New results demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 26, 2015 Category: Science Source Type: news

Statins Show Benefit in Hepatitis C Compensated CirrhosisStatins Show Benefit in Hepatitis C Compensated Cirrhosis
Statins, long thought to be hepatotoxic in patients with advanced liver disease, might actually slow decompensation and prolong survival, but a randomized trial is needed to prove it. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 25, 2015 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Drinking just 1 or 2 alcoholic drinks a day linked to liver disease
(European Association for the Study of the Liver) According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. A new worldwide study presented at The International Liver CongressTM 2015 has shown the significant influence of daily drinking on this disease burden. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 25, 2015 Category: Global & Universal Source Type: news

DCV, SOF & RBV comb. effective/tolerated in HCV with adv, cirrhosis / post-transplant recurrence
(European Association for the Study of the Liver) Phase 3 results presented today at The International Liver Congress™ 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 25, 2015 Category: Global & Universal Source Type: news

Sofosbuvir + peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients
(European Association for the Study of the Liver) Results presented today at The International Liver Congress™ 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 25, 2015 Category: Global & Universal Source Type: news

Liver Cirrhosis: Inpatient Mortality Is DecreasingLiver Cirrhosis: Inpatient Mortality Is Decreasing
In-hospital mortality is decreasing for patients with cirrhosis, but outpatient mortality is unclear. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 24, 2015 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Merck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
Dateline City: VIENNA Data Sets Include Treatment-Naïve, Treatment-Experienced and HIV Co-Infected Patients with Chronic Hepatitis C Virus Genotypes 1, 4 or 6 Infection Merck Remains on Track to Submit New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) in First Half of 2015 VIENNA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentations of data from the company’s ongoing C-EDGE pivotal Phase 3 clinical trial program evaluating the investigational once-daily table...
Source: Merck.com - Research and Development News - April 24, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Source Type: news

Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease
Dateline City: VIENNA C-SURFER Trial is First to Investigate an All-Oral Ribavirin-Free Hepatitis C Treatment Regimen in Treatment-Naïve and Treatment-Experienced Patients with Advanced Chronic Kidney Disease Infected with Hepatitis C Virus Genotype 1 VIENNA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data from C-SURFER, the company’s Phase 2/3 clinical trial evaluating the investigational once-daily treatment regimen of grazoprevir (100mg...
Source: Merck.com - Research and Development News - April 23, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Source Type: news

All-oral, DAA options for HCV effective & well tolerated in patients with decompensated cirrhosis
(European Association for the Study of the Liver) Interim data presented today at The International Liver CongressTM 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C is well tolerated and highly effective in patients with decompensated cirrhosis. Sustained virologic response at four weeks was shown to be: sofosbuvir/ribavirin: 75 percent; sofosbuvir/simeprevir: 77 percent; sofosbuvir/simeprevir/ribavirin: 81 percent. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 23, 2015 Category: Biology Source Type: news

Lupin launches anti-bacterial Zaxine tablets in Canada
Zaxine 550 mg (rifaximin) is a long-term antibiotic treatment drug for adults living with HE, a complication of liver disease (cirrhosis). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 20, 2015 Category: Pharmaceuticals Source Type: news

Alkaline Phosphatase, Bilirubin Levels and Outcomes in PBCAlkaline Phosphatase, Bilirubin Levels and Outcomes in PBC
Do alkaline phosphatase and bilirubin levels help clinicians predict disease outcome in patients with primary biliary cirrhosis? Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Mouth, as well as gut, could hold key to liver disease flare-ups
In a recent study, researchers predicted which cirrhosis patients would suffer inflammations and require hospitalization by analyzing their saliva, revealing a new target for research into a disease that accounts for more than 30,000 deaths in the United States each year. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 17, 2015 Category: Science Source Type: news

Mouth, as well as gut, could hold key to liver disease flare-ups
(Virginia Commonwealth University) In a recent study, Virginia Commonwealth University School of Medicine researchers predicted which cirrhosis patients would suffer inflammations and require hospitalization by analyzing their saliva, revealing a new target for research into a disease that accounts for more than 30,000 deaths in the United States each year. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 17, 2015 Category: Global & Universal Source Type: news

The CNIO links telomeres to the origins of liver diseases such as chronic hepatitis and cirrhosis
This study is the first to show that alterations in the functioning of telomeres lead to changes in the liver that are common to diseases associated with an increased risk of liver cancer. This finding provides the basis for understanding the molecular origin of these diseases, as well as identifying new therapeutic strategies for their prevention and control. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 16, 2015 Category: Cancer & Oncology Source Type: news

Alcohol Dependency in Our Family and How We Struggle With It
He was in his 50s when he died. We put all of his earthly possessions into three banana boxes and placed them into the trunk of our '63 Chevy station wagon. The key to the single (twin bed) hotel room was returned to the front desk clerk. Ironically, this was the same job he once held before alcohol got him too pickled to keep his balance for longer than half an hour. They said it was too hard for him to stand up. By the time I met Uncle Ivan he had probably been drinking (heavily) for the previous four decades. There was a certain odor about him that smelled of piss vinegar and Old Spice. I remember the whiskers on his ch...
Source: Healthy Living - The Huffington Post - April 11, 2015 Category: Consumer Health News Source Type: news

Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The International Liver CongressTM 2015
Dateline City: KENILWORTH, N.J. Congress Highlights Include Results from Trials in a Wide Range of HCV Patients -- Patients with Chronic Kidney Disease, HIV Co-infection, Cirrhosis, and Prior Treatment Failures Company Remains on Track for NDA Filing with the U.S. FDA During First Half of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis C virus (HC...
Source: Merck.com - Corporate News - April 8, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News Source Type: news